SLC5A2 and type 2 diabetes mellitus: In the last few years, the efficacy of SGLT2-i drugs in reducing all-cause and cardiovascular death and hospitalizations for heart failure in patients affected by heart failure with reduced and preserved ejection fraction (HFrEF/HFpEF), regardless of the T2DM presence, has been highlighted [32].